The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis

Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette's Sy...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neuroscience 2020-03, Vol.14, p.158-158
Main Authors: Maguire, Gerald A, Nguyen, Diem L, Simonson, Kevin C, Kurz, Troy L
Format: Article
Language:English
Subjects:
Adults
Age
Antagonism
Antagonists
Anxiety
Brain research
Children
Dopamine
Dopamine D1 receptors
Dopamine D2 receptors
Drug therapy
ecopipam
Etiology
FDA approval
Gilles de la Tourette syndrome
Medical imaging
medication
Neuroscience
olanzapine
pharmacologic
risperidone
Stuttering
Twins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette's Syndrome in that both begin in childhood, follow a similar male to female ratio of 4:1, respond to dopamine antagonists, and symptomatically worsen with dopamine agonists. In recent years, advances in the neurophysiology of stuttering have helped further guide pharmacological treatment. A newer medication with a novel mechanism of action, selective D1 antagonism, is currently being investigated in FDA trials for the treatment of stuttering. D1 antagonists possess different side-effect profiles than D2 antagonist medications and may provide a unique option for those who stutter. In addition, VMAT-2 inhibitors alter dopamine transmission in a unique mechanism of action that offers a promising treatment avenue in stuttering. This review seeks to highlight the different treatment options to help guide the practicing clinician in the treatment of stuttering.
ISSN:1662-4548
1662-453X
1662-453X
DOI:10.3389/fnins.2020.00158